Nonalcoholic Steatohepatitis (NASH) Market | NASH Market Research Report
DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology and Market Forecast-2028’ Nash Market report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NASH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study Period: 2016-2028
Nonalcoholic Steatohepatitis – Disease Understanding and Treatment Algorithm
Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of non-alcoholic fatty liver disease (NAFLD), caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Nonalcoholic Steatohepatitis Epidemiology
The Nonalcoholic Steatohepatitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
Nonalcoholic Steatohepatitis Drug Chapters
This segment of the Nonalcoholic Steatohepatitis (NASH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugsNonalcoholic Steatohepatitis Market Outlook
The Nonalcoholic Steatohepatitis (NASH) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Nonalcoholic Steatohepatitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
Key players in the market of NASH are Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius Therapeutics, Conatus Pharmaceuticals, Galectin Therapeutics, Immuron, NGM Biopharmaceuticals, Akcea Therapeutics and others. We expect that the launch of emerging therapies will fill the treatment void in the near future.
Nonalcoholic Steatohepatitis Report Insights
- Nonalcoholic Steatohepatitis Patient Population
- Nonalcoholic Steatohepatitis Therapeutic Approaches
Nonalcoholic Steatohepatitis Report Key Strengths
- 10 Years Nonalcoholic Steatohepatitis Forecast
- NASH 7MM Coverage
- Nonalcoholic Steatohepatitis Epidemiology Segmentation
Nonalcoholic Steatohepatitis Report Assessment
- NASH Pipeline Product Profiles
- NASH Market Drivers and NASH Market Barriers
Key Benefits
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Nonalcoholic Steatohepatitis market
